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Introduction 
Coronavirus disease of 2019 (COVID-19) is caused by 
a severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2). SARS-CoV-2 belongs to the betacoronavirus 
family which includes severe acute respiratory syndrome 
coronavirus (SARS-CoV-1) and Middle East respiratory 
syndrome coronavirus (MERS-CoV).1 All viruses from 
the betacaronavirus family pose a public health threat as 
they are known to cross species barriers and lead to high 
pathogenicity and mortality in humans.1 The COVID-19 
global health pandemic has resulted in 8,242,999 cases and 
445,535 deaths worldwide as of June 18, 2020.2 There are 
currently no vaccines available to prevent infection with 
COVID-19 and no proven drug therapies. While the central 
nervous system complications of COVID-19 are becoming 
increasingly recognized including headache, seizure, en-
cephalopathy, and cerebrovascular event, neuromuscular 
complications of COVID-19 are just beginning to be docu-
mented.3-4 Patients with several neuromuscular disorders 
may also be at increased risk for exacerbation or progres-
sion of underlying disease due to COVID-19 associated 
respiratory muscle injury and long-term usage of immuno-
suppressive or immunomodulatory therapies.5 
In this review we focus our discussion on two ways that 
COVID-19 critically impacts neuromuscular medicine: (1) 
serious complications and outcomes associated with the vi-
ral infection and; (2) management considerations for neu-
romuscular patients on immunotherapies during the CO-
VID-19 pandemic.   A comprehensive PUBMED literature 
search was completed on June 13, 2020 using keywords 
“coronavirus” and “neurology,” yielding a total of 547 pub-
lications. All articles in the English language were reviewed, 
and those with detailed information on neuromuscular 
manifestations were included. 
Neuromuscular Complications of COVID-19
Guillain-Barré syndrome (GBS)
At the time of this literature search, the most common-
ly reported neuromuscular complication of COVID-19 was 
GBS. While GBS has been infrequently described in SARS-
CoV-1 and MERS-CoV, it seems to be relatively common in 
COVID-19.5 Up to the search date, 27 cases of COVID-19 
associated GBS were reported, 3 of whom were described 
as the Miller Fisher variant.7-25 Report origins were world-
wide including Austria (1),11 China (1),23 France (1),9 Ger-
many (1),17 Italy (10),7-8, 14,16,21 Iran (1),18 Morocco (1),20 Spain 
(3), 24-25 Switzerland (3),12 Turkey (1),1 and United States 
(4).10,15,19,22 Table 1 shows the essential characteristics and 
clinical courses of the 27 GBS cases. The mean age was 
59.8 years, with male cases (63%) predominating over fe-
males (37%). The mean interval duration between the ini-
tial onset of COVID-19 symptoms and the appearance of 
neurologic symptoms was 10.7 days. Fever preceded GBS 
symptoms in 17 (63%) patients. In 2 (7.4%) GBS patients, 
there were no preceding symptoms suggesting COVID-19 
infection. Eleven patients were tested for anti-ganglioside 
antibodies, and only one returned positive for GD1b-IgG.24 
SARS-CoV-2 viral PCR was performed in cerebrospinal 
fluid (CSF) of 15 patients, and all were negative. On MRI, 
nerve root enhancement was observed in four, and bilateral 
facial nerve enhancement was seen in one patient.21 Elec-
trodiagnostic (EDX) testing was completed in 23 patients. 
Among them, 16 (69.6%) were found to reveal demyelinat-
ing, 6 (26%) axonal, and 1 (4.3%) mixed axonal and demye-
linating features. Mechanical ventilation was administrated 
in 12 (44%) patients.
The most common immunotherapy was intravenous 
immunoglobulin (IVIG), administered in 24 (88.9%) pa-
tients; and plasmapheresis was used in 2 (7.4%). Hydroxy-
chloroquine and/or antiviral therapies were added to treat-
ment regimens in 7 (25.9%) cases. In regard to overall out-
come, 16 (59.3%) patients showed clinical improvement or 
achieved full or near full recovery, 9 (33.3%) did not show 
significant improvement or had a worsening clinical status. 
Of the 16 patients who improved, all but 2 were treated with 
IVIG. For 2 (7.4%) patient outcomes were not reported.
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Myopathy and hyperCKemia
Myopathy and hyperCKemia are frequently reported 
complications of COVID-19. A retrospective case series by 
Mao et al. 4 included 214 COVID-19 patients from Wuhan, 
China, and found 10.7% of patients had evidence of skeletal 
muscle injury, defined as muscle pain with creatine kinase 
(CK) levels of being >200 U/L. Of the 88 patients with 
severe infection, the incidence of skeletal muscle injury 
increased to 19.3%, compared to only 4.8% in 126 patients 
with mild infection. Zhang et al.28 analyzed another group of 
95 patients with COVID-19 in Wuhan and reported an in-
cidence of 29.5% with hyperCKemia (defined as CK >200 
U/L). Similarly, a higher incidence (43.8%) of hyperCK-
emia was observed in 32 patients with severe infection.28 
Romero-Sanchez et al.29 analyzed a group of 841 patients 
hospitalized with COVID-19 in Spain. In their analysis, hy-
perCKemia was found in 73 (9.2%), and clinical evidence 
of myopathy was seen in 26 (3.1%) patients, 3 of which had 
EDX evidence of myopathy. Their patients may include 
cases of critical care myopathy, as a multivariate analysis re-
ported longer ICU stay was the only independent predictor 
in the development of myopathy.29 A few additional studies 
reported rhabdomyolysis in the setting of COVID-19.   Jin 
et al.30 described a 60-year-old man with CK of 11,842 U/L 
and elevated myoglobin of >12.00 mg/L. His clinical symp-
toms and CK improved with aggressive fluid therapy. Guan 
et al.31 defined rhabdomyolysis as the presence of muscle 
pain, weakness and CK level that was 10 times the upper 
limit of normal and found a low incidence of 0.2% among 
1099 patients. 
Neuromuscular Junction Disorders 
Patients with neuromuscular junction disorders such 
as myasthenia gravis (MG) are known to be vulnerable to 
infection leading to exacerbations.32 Chronic immunosup-
pressive or immunomodulatory therapy and thymectomy 
also place these patients at increased risk for infections.33 
Concerns have been raised in that MG patients are at higher 
risk for contracting COVID-19 or developing exacerbations 
secondary to coronavirus infection.34   To date, there are a 
total of 7 MG patients reported as having contracted CO-
VID-19.35,42,44   Table 2 outlines the clinical characteristics, 
treatment regimes, and outcomes of these patients. All 7 
cases reside in the United States and all had generalized 
MG. Six were positive for acetylcholine receptor antibody, 
and one was positive for muscle specific tyrosine kinase 
antibody. Three patients required mechanical ventilation 
for respiratory failure, and one required significant supple-
  
Author Age/sex MGFA 
Class at 
COVID-19 
diagnosis 
Antibody 
status 
Thymus 
status 
MG treatment 
at time of 
infection 
Signs and symptoms MG and COVID-19 
treatment 
Outcome MG course during 
COVID-19  
Anand35 57M 1 AChR-Ab+ thymectomy AZA 50 mg/day sore throat, cough AZA 50 mg daily, 
HCQ, AZM, TOZ 
Required ventilation 
but extubated on day 7 
No exacerbation  
Anand35 64M  Remission AChR-Ab+ thymectomy MMF 1000 mg 
BID, Pred 5 mg 
QOD 
cough, chill Pred 10mg daily for 9 
days then 5mg QOD, 
HCQ, AZM, CTX 
Required ventilation 
then tracheostomy 
No exacerbation 
Anand35 90F 1 AChR-Ab+ No 
thymectomy 
MMF 1000 mg 
BID, Pred 30 
mg/day IVIG 
0.8 g/kg  
monthly 
shortness of breath, 
cough, fever 
Pred 25mg daily for 6 
days then 20mg 
daily, IVIG 
continued, HCQ, 
AZM, CTX 
Required high flow 
oxygen therapy 
without need for 
ventilation 
No exacerbation 
Anand35 42F 2B MuSK-Ab + No 
thymectomy 
Pred 5 mg 
alternating with 
2.5 mg QOD 
sore throat, myalgia, 
worsening dysphagia, 
neck weakness, 
diplopia 
Pred 20mg daily, 
IVIG 2 g/kg 
No respiratory support 
required 
Exacerbation  
Anand35 64F 1 AChR-Ab+ No 
thymectomy 
MMF 750BID, 
Pred 15 mg/day 
cough, night sweat, 
chill 
Pred 15mg daily No respiratory support 
required 
No exacerbation 
Delly42 56F 2B AChR-Ab+ No 
thymectomy 
Pyridostigmine 
60mg QID, 
Pred 40mg/day, 
IVIG 1.3 g/kg 
every 2 weeks), 
HCQ 200mg 
BID for CTD 
dyspnea, fever, 
myalgia, proximal 
limb weakness, 
respiratory failure  
Pred 80mg daily, 
IVIG at 0.4 g/kg for 5 
days then 0.65 g/kg 
for 2 days 
Required ventilation 
then extubated on day 
13 
Exacerbation with crisis  
Ramaswamy44 42F 2B AChR-Ab+ Thymoma 
without 
thymectomy 
MMF 1000 
BID, 
pyridostigmine 
60mg QID, 
Pred 30mg/day, 
PLEX q4week 
fever, chill, cough, 
anosmia, ageusia 
PLEX was held, 
home regime 
continued 
No respiratory support 
required 
No exacerbation 
Table 2: A list of myasthenia gravis patients with COVID-19.
Abbreviations: MGFA, Myasthenia Gravis Foundation of America; MG, myasthenia gravis; AChR-Ab, acetylcholine receptor antibody; 
AZA, azathioprine; HCQ: hydroxychloroquine; AZM, azithromycin; TOZ, tocilizumab; MMF, mycophenolate mofetil; Pred, Prednisone; 
CTX, ceftriaxone; IVIG, intravenous immunoglobulin; MuSK-Ab, muscle specific tyrosine kinase antibody; CTD, connective tissue dis-
ease; PLEX, plasmapheresis.
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mental oxygen. Two patients showed definite signs of MG 
exacerbation on examination, however, such an impres-
sion could have been hindered by the need for ventilation 
and sedation in COVID-19 patients with severe pulmonary 
dysfunction. Outcomes were fairly good in six patients, with 
only one patient remaining intubated at day 35.35
Acute Myelitis 
So far there has been no case reports of a motor neuron 
disorder associated with COVID-19 infection. Two cases 
of myelitis have been reported 36,37. Zhao et al.36 described a 
66-year-old man who developed lower extremity weakness 
with bowel and bladder incontinence followed by flaccid 
lower extremity paralysis, hyporeflexia, and a thoracic sen-
sory level. Spinal cord imaging and CSF studies were not 
performed on this patient. He was treated empirically with 
IVIG and methylprednisolone, which led to some clinical 
improvement. Munz et al.37 described a 60 year-old-man 
who presented with lower extremity weakness and bladder 
dysfunction 8 days after developing respiratory symptoms. 
CSF studies revealed a lymphocytic pleocytosis and nega-
tive SARS-CoV-2 PCR testing.  MRI spine imaging revealed 
T2 hyperintensity in the thoracic spinal cord. He was treated 
with methylprednisolone which led to clinical improvement. 
Management Considerations in Neuromuscular 
Patients Receiving Immunotherapy 
Neuromuscular patients who are on immunosuppres-
sive and immunomodulatory agents as well as those with 
respiratory and/or bulbar dysfunction secondary to neu-
romuscular disease should be considered high risk for se-
vere COVID-19 infection and complications.5,38 Patients 
should be encouraged to notify their healthcare provider 
immediately if there are signs suspicious for COVID-19 
infection.  Although there are currently no evidence-based 
guidelines for the management of neuromuscular disease 
in the current COVID-19 pandemic, there have been rec-
ommendations made by the French Rare Health Care for 
Neuromuscular disease Network (FILNEMUS) as well 
as recommendations made in a recent review article in 
Neurology by Guidon and Amato.5,39   Proposed treatment 
strategies for initiating and managing immunosuppressants 
in neuromuscular patients are summarized in Table 3.
An MG expert panel has made recommendations for 
the management of MG patients during COVID-19, stating 
that therapy decisions should be individualized and made 
jointly with the patient’s overall healthcare team.34 The 
general recommendation for MG patients who contract 
COVID-19 is to continue current treatment, but cortico-
 
Table 3. Recommended adjustment of immunotherapy in neuromuscular patients.  
Medication Class Examples Patients initiating 
treatment 
Patients already on treatment 
Corticosteroids Prednisone, 
Methylprednisolone, 
Deflazacort 
Treat at lowest 
effective dose 
Continue therapy regimen  
If treated with intravenous corticosteroids, consider home infusion, 
intramuscular or oral dosing.   
Immunosuppressive Therapy Azathioprine, 
Mycophenolate 
mofetil, Methotrexate, 
Tacrolimus, 
Cyclosporine 
Consider delaying 
initiation in stable 
patients with mild 
disease. Consider 
spacing-out lab 
monitoring  
Continue therapy regimen   
Immunomodulatory Therapy IVIG/SCIG, 
Plasmapheresis 
Consider initiating 
home infusions for 
immunoglobulin 
Consider home infusions, reducing frequency in stable patients.   
Cell depleting Therapy Rituximab, 
Cyclophosphamide 
Avoid initiating unless 
no alternative 
Consider postponing infusions, spacing out dosing or switching to 
subcutaneous therapy 
Complement Inhibitors Eculizumab Consider need for 
immunizations, 
exposure to facilities 
during infusions 
Likely does not increase COVID-19 risk 
Non-immunomodulatory 
infusions, gene therapy 
Edaravone, 
Nusinersen/zolgensma
, Patisiran/Inotersen, 
Lumizyme/myozyme 
Consider initiating 
home infusions. 
SMA1&2 should not 
delay initiation of 
Nusinersen/Zolgensm
a. SMA3&4 could 
consider delay 
Consider home infusions, risk of exposure in facilities versus risk of 
treatment interruption.  
Recommend not delaying Nusinersen/Zolgensma infusions in 
children, could consider delay in adolescent or adult patients.  
Modified from Guido & Amato.5 
 
Table 3: Recommended adjustment of immunotherapy in neuromuscular patients.
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steroid dosage may need to be increased as in stress-dose 
protocols.34 If patients are hospitalized it is recommended 
that immune depleting agents be held, especially those that 
deplete B-cell lines that would directly impair development 
of antibody-mediated immunity to the novel coronavirus, 
but standard immunosuppressive agents such as azathio-
prine or mycophenolate mofetil may be continued, given 
their long wash-out period.34 Additionally, it is important to 
be cautious with investigational treatments for COVID-19 
in MG patients such as hydroxychloroquine and azithromy-
cin as these have been associated with myasthenic worsen-
ing.5,35
Discussion 
There is rapidly growing evidence that COVID-19 in-
fection can be associated with neuromuscular complica-
tions, and thus neurologists and clinicians should be vigilant 
of these manifestations. The precise mechanism of coro-
navirus induced neurological and neuromuscular compli-
cations are not completely understood.  Several theories 
have been postulated including neurotropic mechanisms 
of direct viral invasion of the peripheral nervous system 
versus immune mediated injury.5,40   Both SARS-CoV-1 
and SARS-CoV-2 use the angiotensin converting enzyme 
2 (ACE2) to gain entry into the cells.43 ACE2, which plays 
a critical role in the renin-angiotensin-aldosterone system, 
has been identified on a variety of human organs particular-
ly lung epithelium and small intestine enterocytes, provid-
ing an entry point for the virus.43 ACE2 receptors are also 
expressed in the nervous system including membranes of 
spinal cord neurons, as well as skeletal muscle.4,36,43 There is 
speculation that ACE2 may serve as a mechanism for neu-
rologic complications seen in COVID-19 leading to central 
nervous system involvement including acute myelitis.4,36,37 
However, it is unclear whether muscle symptoms described 
in COVID-19 are related to viral invasion via ACE2 located 
on skeletal muscle or due to the immune response caus-
ing up-regulation of cytokines leading to inflammation and 
muscle damage.4 Future investigation as well as long-term 
follow up of patients with neuromuscular complications as-
sociated with COVID-19 will likely clarify our understand-
ing and improve management strategies for these patients. 
Apart from hyperCKemia and myalgia, GBS appears to 
be the most commonly described neuromuscular complica-
tion associated with COVID-19. It is speculated that there 
is an autoimmune reaction in which SARS-CoV-2 elicits an 
immune response targeting self-epitopes leading to nervous 
system involvement described as “molecular mimicry.”11,13,18 
Such mechanisms have been previously proposed in bacte-
rial or viral infections that commonly precede GBS (e.g., 
Campylobacter, cytomegalovirus, Epstein-Barr virus and 
Zika virus). 5,22,41 COVID-19 could have a para-infectious as-
sociation with GBS rather than the more recognized post-
infectious pattern classically reported. All 15 GBS patients 
reported had negative CSF SARS-CoV-2 PCR testing, ar-
guing against direct viral invasion or intrathecal viral rep-
lication. Improvement with immunotherapy and perhaps 
the discovery of GD1b antibodies in one patient favor an 
immune mediated mechanism. 
It is important to realize that preceding COVID-19 
symptoms may not be evident prior to the onset of GBS in 
some patients.13,23 These patients could be asymptomatic 
carriers, or they could have an overlapping COVID-19/GBS 
course. COVID-19 should be considered in the differential 
diagnosis for patients presenting with acute neurologic 
symptoms suggestive of GBS, even in cases without preced-
ing respiratory distress. 
A significant portion of patients with COVID-19 de-
velop respiratory failure in need of long ICU stay. It will also 
be important to study an association of COVID-19 with the 
possible occurrence of critical illness myopathy and critical 
illness neuropathy common to patients who require inten-
sive care management. 
Finally, neuromuscular patients that are on immuno-
suppression or those with respiratory or bulbar dysfunction 
who should be considered as high risk for severe complica-
tions of COVID-19 should be judiciously monitored. At this 
time, recommendations for immunotherapy adjustment are 
mostly speculative. Data collection via large case series col-
lection or disease registry is needed before evidence-based 
recommendations can be made. 
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